Aethlon Receives Clearance From Drug Controller General Of India For Potential Phase 1 Trial Of Its Hemopurifier In Oncology
Portfolio Pulse from Bill Haddad
Aethlon Medical, Inc. (AEMD) has received clearance from the Drug Controller General of India to potentially conduct a Phase 1 trial of its Hemopurifier in oncology. This marks a significant step in the company's efforts to expand its clinical trials globally.
October 10, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aethlon Medical's clearance to potentially conduct a Phase 1 trial of its Hemopurifier in oncology in India could boost the company's global clinical trial efforts.
The clearance from the Drug Controller General of India is a significant regulatory milestone for Aethlon Medical. It allows the company to potentially conduct a Phase 1 trial of its Hemopurifier in oncology in India, which could expand its clinical trials globally and potentially lead to increased investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100